The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

AIM: The “2026 Guideline for the Early Management of Patients With AIS” replaces the “2018 Guidelines for the Early Management of Patients With AIS” and the 2019 update to reflect recent advances in ...

Expanded eligibility for advanced ischemic stroke therapies and the first detailed recommendations pediatric stroke care are ...

This “long overdue” update expands the pools of patients eligible for thrombolysis and thrombectomy, and tackles pediatric ...

Alteplase, a “clot-buster” medication used to treat ischemic stroke, acute myocardial infarctions, and acute pulmonary ...

The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

Manual review of electronic health records (EHRs) to screen for contraindications to thrombolysis during stroke evaluation is ...

The American Heart Association and American Stroke Association have issued an updated guideline for the diagnosis and treatment of acute ischemic stroke.The new guideline, published in Stroke, ...

WILLOWBROOK, Ill., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Pharmazz, Inc. today announced the presentation of positive interim results from its ongoing Phase IV clinical study of sovateltide (Tycamzzi®) in ...

Expanded eligibility for advanced stroke therapies and new recommendations for diagnosing and treating stroke in children and ...

Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion TherapiesData Presented at International Stroke ConferenceData Show That LT3001 Delivers Meaningful ...